These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 19054672)

  • 1. Discovery of novel spirocyclopropyl hydroxamate and carboxylate compounds as TACE inhibitors.
    Guo Z; Orth P; Wong SC; Lavey BJ; Shih NY; Niu X; Lundell DJ; Madison V; Kozlowski JA
    Bioorg Med Chem Lett; 2009 Jan; 19(1):54-7. PubMed ID: 19054672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
    Sheppeck JE; Gilmore JL; Tebben A; Xue CB; Liu RQ; Decicco CP; Duan JJ
    Bioorg Med Chem Lett; 2007 May; 17(10):2769-74. PubMed ID: 17368021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A molecular modeling analysis of novel non-hydroxamate inhibitors of TACE.
    Sheppeck JE; Tebben A; Gilmore JL; Yang A; Wasserman ZR; Decicco CP; Duan JJ
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1408-12. PubMed ID: 17188861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors: Part I--discovery of two binding modes.
    Zhu Z; Mazzola R; Sinning L; McKittrick B; Niu X; Lundell D; Sun J; Orth P; Guo Z; Madison V; Ingram R; Beyer BM
    J Med Chem; 2008 Feb; 51(4):725-36. PubMed ID: 18247549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The discovery of novel tartrate-based TNF-alpha converting enzyme (TACE) inhibitors.
    Rosner KE; Guo Z; Orth P; Shipps GW; Belanger DB; Chan TY; Curran PJ; Dai C; Deng Y; Girijavallabhan VM; Hong L; Lavey BJ; Lee JF; Li D; Liu Z; Popovici-Muller J; Ting PC; Vaccaro H; Wang L; Wang T; Yu W; Zhou G; Niu X; Sun J; Kozlowski JA; Lundell DJ; Madison V; McKittrick B; Piwinski JJ; Shih NY; Arshad Siddiqui M; Strickland CO
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1189-93. PubMed ID: 20022498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and SAR of hydantoin TACE inhibitors.
    Yu W; Guo Z; Orth P; Madison V; Chen L; Dai C; Feltz RJ; Girijavallabhan VM; Kim SH; Kozlowski JA; Lavey BJ; Li D; Lundell D; Niu X; Piwinski JJ; Popovici-Muller J; Rizvi R; Rosner KE; Shankar BB; Shih NY; Siddiqui MA; Sun J; Tong L; Umland S; Wong MK; Yang DY; Zhou G
    Bioorg Med Chem Lett; 2010 Mar; 20(6):1877-80. PubMed ID: 20172725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of beta-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors.
    Duan JJ; Chen L; Lu Z; Xue CB; Liu RQ; Covington MB; Qian M; Wasserman ZR; Vaddi K; Christ DD; Trzaskos JM; Newton RC; Decicco CP
    Bioorg Med Chem Lett; 2008 Jan; 18(1):241-6. PubMed ID: 18032037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha,Beta-cyclic-beta-benzamido hydroxamic acids: Novel oxaspiro[4.4]nonane templates for the discovery of potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
    Ott GR; Asakawa N; Liu RQ; Covington MB; Qian M; Vaddi K; Newton RC; Trzaskos JM; Christ DD; Galya L; Scholz T; Marshall W; Duan JJ
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1288-92. PubMed ID: 18234496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
    Duan JJ; Chen L; Lu Z; Jiang B; Asakawa N; Sheppeck JE; Liu RQ; Covington MB; Pitts W; Kim SH; Decicco CP
    Bioorg Med Chem Lett; 2007 Jan; 17(1):266-71. PubMed ID: 17027261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket.
    Huang A; Joseph-McCarthy D; Lovering F; Sun L; Wang W; Xu W; Zhu Y; Cui J; Zhang Y; Levin JI
    Bioorg Med Chem; 2007 Sep; 15(18):6170-81. PubMed ID: 17606376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, preliminary biological evaluation and molecular modeling of some new heterocyclic inhibitors of TACE.
    Sengupta P; Puri CS; Chokshi HA; Sheth CK; Midha AS; Chitturi TR; Thennati R; Murumkar PR; Yadav MR
    Eur J Med Chem; 2011 Nov; 46(11):5549-55. PubMed ID: 21963348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and structure-activity relationship of a novel, non-hydroxamate series of TNF-alpha converting enzyme inhibitors.
    Gilmore JL; King BW; Asakawa N; Harrison K; Tebben A; Sheppeck JE; Liu RQ; Covington M; Duan JJ
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4678-82. PubMed ID: 17576061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and activity of tryptophan sulfonamide derivatives as novel non-hydroxamate TNF-alpha converting enzyme (TACE) inhibitors.
    Park K; Gopalsamy A; Aplasca A; Ellingboe JW; Xu W; Zhang Y; Levin JI
    Bioorg Med Chem; 2009 Jun; 17(11):3857-65. PubMed ID: 19410464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of 3,3-piperidine hydroxamate analogs as selective TACE inhibitors.
    Lombart HG; Feyfant E; Joseph-McCarthy D; Huang A; Lovering F; Sun L; Zhu Y; Zeng C; Zhang Y; Levin J
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4333-7. PubMed ID: 17531482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.
    Levin JI; Chen JM; Laakso LM; Du M; Du X; Venkatesan AM; Sandanayaka V; Zask A; Xu J; Xu W; Zhang Y; Skotnicki JS
    Bioorg Med Chem Lett; 2005 Oct; 15(19):4345-9. PubMed ID: 16084720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.
    Levin JI; Chen JM; Du MT; Nelson FC; Killar LM; Skala S; Sung A; Jin G; Cowling R; Barone D; March CJ; Mohler KM; Black RA; Skotnicki JS
    Bioorg Med Chem Lett; 2002 Apr; 12(8):1199-202. PubMed ID: 11934588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: optimization of the S3' pocket.
    Mazzola RD; Zhu Z; Sinning L; McKittrick B; Lavey B; Spitler J; Kozlowski J; Neng-Yang S; Zhou G; Guo Z; Orth P; Madison V; Sun J; Lundell D; Niu X
    Bioorg Med Chem Lett; 2008 Nov; 18(21):5809-14. PubMed ID: 18835710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based rational design of peptide hydroxamic acid inhibitors to target tumor necrosis factor-α converting enzyme as potential therapeutics for hepatitis.
    Wu D; Gu Q; Zhao N; Xia F; Li Z
    J Drug Target; 2015 Dec; 23(10):936-42. PubMed ID: 26061299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates.
    Levin JI; Chen JM; Laakso LM; Du M; Schmid J; Xu W; Cummons T; Xu J; Jin G; Barone D; Skotnicki JS
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1605-9. PubMed ID: 16426848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IK682, a tight binding inhibitor of TACE.
    Niu X; Umland S; Ingram R; Beyer BM; Liu YH; Sun J; Lundell D; Orth P
    Arch Biochem Biophys; 2006 Jul; 451(1):43-50. PubMed ID: 16762314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.